Immunocore to Present Phase 1 Data at 2026 SITC Meeting
Immunocore says it will present Phase 1 data for brenetafusp plus KIMMTRAK in metastatic uveal melanoma during a late-breaking oral session at the 2026 SITC meeting.
Related stories
Georgia Banking Co. Shares Trade at $40.15 After Opening at $60
Shares traded at $40.15 after opening at $60 in the company's Nasdaq debut via direct listing. Its prospectus said stockholders would sell up to 7.07 million shares.
M impact | EQUITY | Oct 29, 2026, 07:24 PM UTC
Medical Properties Trust Reports Quarterly Results
Medical Properties Trust reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 07:24 PM UTC
Volkswagen Avoids Puebla Plant Strike With 8.24% Employee Raise
Volkswagen will give employees at its Puebla plant an 8.24% raise this year, averting a strike.
M impact | EQUITY | Oct 29, 2026, 07:23 PM UTC
Federal Signal Reports Q3 2026 Revenue of $655.5M, EPS of $1.29
Third-quarter net income was $79.6 million. Revenue rose 18.1%, net income 16.9% and diluted EPS 16.2% from the prior-year quarter.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Peoples Bancorp Reports Third-Quarter 2026 Revenue of $119.5 Million
Revenue rose 3.8% year over year to $119.5 million. Net income increased 10.6% to $32.6 million, while diluted EPS rose to $0.91 from $0.83.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Axalta Reports Third-Quarter 2026 Revenue of $1.31 Billion
Revenue rose 1.8% year over year to $1.31 billion, while net income declined 13.6% to $95 million and diluted EPS fell 13.7% to $0.44.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC